Pharmicell Co., Ltd.
Clinical trials sponsored by Pharmicell Co., Ltd., explained in plain language.
A biopharmaceutical company developing cell and gene therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Stem cell therapy for cirrhosis: Five-Year safety watch Results expected Dec 2026 (estimated)
-
Can a single stem cell shot save a scarred liver?
Disease control Recruiting nowResearchers are testing whether a single injection of a patient's own bone marrow stem cells, delivered into the liver's main artery, can help people with alcoholic cirrhosis live longer without needing a liver transplant. The trial enrolls about 200 adults with moderate to sever…
Phase 3 • Sponsor: Pharmicell Co., Ltd. • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Stem cell treatment for Post-Surgery ED: safety check underway
Disease control Recruiting nowThis study is a safety follow-up for 32 men who previously received an experimental stem cell treatment (Cellgram-ED) for erectile dysfunction after prostate removal due to cancer. Researchers are monitoring tumor markers, serious side effects, and any cancer recurrence over time…
Sponsor: Pharmicell Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Heart attack stem cell therapy under Long-Term safety watch
Disease control Recruiting nowThis study follows 100 people who received Hearticellgram-AMI, a stem cell treatment for acute heart attacks, to see if any serious side effects appear years later. Researchers are watching for death, new cancers, or immune reactions. The goal is to confirm the treatment's long-t…
Sponsor: Pharmicell Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Stem cell therapy for cirrhosis: Five-Year safety watch
Knowledge-focused Recruiting nowResearchers are following 100 people with alcoholic liver cirrhosis who previously received Cellgram-LC, a stem cell therapy made from their own bone marrow. Over five years, the team checks by phone for serious side effects such as new cancers, immune reactions, or the need for …
Sponsor: Pharmicell Co., Ltd. • Aim: Knowledge-focused
Last updated Sep 21, 2026 19:00 UTC